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Clinical/Scientific Notes
Hepatitis B reactivation during glioblastoma
treatment with temozolomide:
A cautionary note
M.G. Chheda, MD; J. Drappatz, MD; N.J. Greenberger, MD;
S. Kesari, MD, PhD; S.E. Weiss, MD; D.C. Gigas, RN;
L.M. Doherty, RN, NP; and P.Y. Wen, MD
We diagnosed a 50-year-old right-handed Chinese man with a
right temporal glioblastoma in October 2005, after he presented
with headaches and progressive left hemiparesis. He had no sig-
nificant past medical illnesses and no known history of hepatitis,
blood transfusion, or IV drug use. He had immigrated to the
United States 5 years previously from Shanxi Province, China. He
had a craniotomy with gross total tumor resection. He was dis-
charged on rapid dexamethasone taper beginning at 24 mg total a
day; 2.5 weeks later, he was on dexamethasone 4 mg total a day.
Three weeks postresection, he began radiotherapy (60 Gy in 30
fractions over 6 weeks) together with 6 weeks of daily temozolo-
mide (75 mg/m2/day). Liver function tests (LFTs) were normal just
prior to chemotherapy and radiation, except an SGPT 68 U/L
(normal 7 to 56 U/L) (figure). During chemo-radiation therapy, the
nadir of white blood cell count was 5.3 K/L, absolute neutrophil
count 3.89 K/L, and absolute lymphocyte count 0.58 K/L.
Throughout chemo-radiation, his dexamethasone continued at 4
mg total a day; thereafter he tapered down to 0.5 mg total a day.
One week post-radiation, he developed worsening left hemiparesis
as a result of a subdural collection. His dexamethasone dose was
briefly increased from 0.5 mg daily to 2 mg daily. We noticed
elevated LFTs (figure).
One week later, 5 weeks after completing temozolomide, he
was admitted with worsening liver tests (figure). Hepatitis B viral
DNA was 724,000 copies/mL and HBeAb was positive. Alpha feto-
protein was 5 IU/mL (normal 0 to 7.4 IU/mL). His medications
were tolterodine, levetiracetam, and atovaquone (dexamethasone
had been tapered off). Examination revealed a jaundiced man
with a mildly enlarged liver. There was no asterixis or encepha-
lopathy. We started the antiviral agent lamivudine 100 mg daily
and liver tests improved over the next 7 weeks (figure). Hepatitis
B viral DNA reached 797,000 copies/mL before returning to 200
copies/mL.
Three months after completion of radiotherapy with concom-
itant temozolomide, he began treatment with adjuvant temozo-
lomide at 150 mg/m2 daily for 5 days/28 days while continuing
on lamivudine. He received two cycles of therapy, the second of
which was at 175 mg/m2 daily for 5 days/28 days, with no
further elevation in LFTs. He developed multiple drop metasta-
ses in the spine. We discontinued temozolomide and adminis-
tered palliative radiotherapy, together with lomustine and
erlotinib.
Discussion. Worldwide, an estimated 350 million people are
chronic hepatitis B carriers, with approximately 170 million carri-
ers in China and 1.25 million in the United States, most of whom
are asymptomatic.1 Immunosuppressive cytotoxic chemotherapy
increases the risk for hepatitis B reactivation, especially in pa-
tients with lymphoma or breast cancer, those with detectable pre-
chemotherapy HBV DNA load, or whose treatment includes
corticosteroids or anthracyclines.2,3 Prophylactic lamivudine dur-
ing and for 6 months after treatment has been safely administered
in hepatitis B carriers with predominantly hematologic malignan-
cies and should be considered in cancer patients who are
carriers.4,5
We describe a case of hepatitis B reactivation in a man with
glioblastoma who received radiotherapy with concomitant temozo-
lomide and low-dose corticosteroids. The relatively unremarkable
liver tests on October 28, 2005, and subsequent positive tests for
HBsAg, HbcAb IgG, and HBeAb indicated the patient was an
inactive hepatitis B carrier. Chemotherapy is known to activate
hepatitis B in cancer patients. Since his steroid dose was low, it is
likely the immunosuppression from temozolomide played the pre-
dominant role in viral reactivation; however, we cannot be com-
pletely certain that steroids had no role in our particular case.
There are two putative mechanisms of hepatitis B virus reactiva-
tion during chemotherapy: immunosuppression from chemother-
Figure. Liver function test trend with
respect to temozolomide chemotherapy
and lamivudine treatment. a Normal
ranges for the Dana-Farber Cancer In-
stitute laboratory are as follows: serum
bilirubin 0.2 to 1.3 mg/dL, SGOT 14 to
46 U/L, SGPT 7 to 56 U/L, alkaline
phosphatase 38 to 126 U/L. b Normal
ranges for the Brigham and Women’s
Hospital laboratory are as follows: se-
rum bilirubin 0.2 to 1.2 mg/dL, SGOT
9 to 30 U/L, SGPT 7 to 52 U/L, alka-
line phosphatase 36 to 118 U/L. c When
dexamethasone dates have a  symbol,
it indicates that steroids were changed
over several days to the noted dose.
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apy enhances virus replication leading to hepatic toxicity; or
chemotherapy-induced T-cell depletion dampens host response to
viral antigens and allows broader hepatocyte infection. When the
chemotherapy is withdrawn (in our case, at the end of the 6 weeks
of temozolomide), the rebound immune response causes hepato-
cyte destruction.6
Since 2005, the standard treatment for glioblastoma has been
radiotherapy with 6 weeks of daily low-dose concomitant temozo-
lomide, followed by 6 months of adjuvant temozolomide.7 Pro-
longed daily temozolomide dosing is associated with lymphopenia
and an increased risk of opportunistic infections such as Pneumo-
cystis pneumonia. Although reactivation of hepatitis B infection
has not been reported previously in patients with brain tumor
undergoing chemotherapy, the widespread use of prolonged daily
dosing of temozolomide is likely to increase the incidence of this
complication. To avoid this, patients at risk of hepatitis B—either
those who come from endemic areas or those who have high-risk
behaviors—should be considered for hepatitis B screening prior to
initiating temozolomide chemotherapy. If the test for hepatitis B
DNA reveals elevated levels, patients should receive prophylactic
therapy with agents such as lamivudine, adefovir, or entecavir—
all active against hepatitis B—for at least 2 months after chemo-
therapy. Finally, in chemotherapy patients with elevated LFTs,
physicians should include viral hepatitis in the differential diag-
nosis, along with medication-induced hepatotoxicity.
Copyright © 2007 by AAN Enterprises, Inc.
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VIDEO Periodic alternating nystagmus in
isolated nodular infarction
H.-S. Jeong, MD; J.Y. Oh, MD; J.S. Kim, MD; J. Kim, MD;
A.Y. Lee, MD; and S.-Y. Oh, MD
Periodic alternating nystagmus (PAN) is characterized by periodic
reversal of horizontal jerky nystagmus with a null period of sev-
eral seconds. Damage to the uvulonodulus or to their connections
with the brainstem vestibular nuclei has been suggested as a
mechanism of PAN.1,2 However, PAN has rarely been reported in
circumscribed cerebellar lesion.3
We report a patient with isolated nodular infarction who
developed PAN without fixation in association with perverted
head-shaking nystagmus (HSN) and loss of tilt suppression of
the postrotatory nystagmus. This is the first report of PAN in
circumscribed cerebellar infarction, and provides further
evidence that PAN occurs due to dysfunction of cerebellar
nodulus.
Case report. A 69-year-old man with a history of hyperten-
sion developed acute vertigo with nausea/vomiting and postural
imbalance. On examination, we observed spontaneous horizon-
tal nystagmus in the primary position which reversed its direc-
tion with a cycle of approximately 2 minutes and a transition
period of several seconds by using video Frenzel goggles
(SLMED, Seoul, Korea) (see the video on the Neurology Web
site at www.neurology.org). The horizontal nystagmus re-
mained in up- and down-gazes with decreased amplitude. Peri-
odic head turn was not observed. With fixation, the nystagmus
disappeared. Downbeat nystagmus was induced for about 10
seconds by horizontal head-shaking for 20 seconds (video).
Gaze-evoked nystagmus or saccadic dysmetria was not ob-
served. Horizontal and vertical smooth pursuit appeared to be
normal for his age. Horizontal head thrust tests were normal.
His gait was ataxic, but no limb dysmetria was present on
finger-to-nose and heel-to-shin test.
Somatosensory and brainstem auditory evoked potentials
and audiogram were normal. Bithermal caloric tests showed
symmetric responses. Sinusoidal harmonic accelerations (peak
velocity: 50 °/second, frequency range: 0.02 to 0.32 Hz) showed
normal gains and phases of the vestibulo-ocular reflex (VOR).
Time constants (TCs) of the per- and postrotatory nystagmus
during step velocity rotations (peak velocity: 100 °/second, ac-
celeration and deceleration: 100 °/second2, duration: 60 sec-
onds) were mildly increased at 18.3 seconds (normal: 14.7
seconds) and TCs of the postrotatory nystagmus were not sup-
pressed by forward head tilt (mean: 18.0 seconds). Diffusion-
Additional material related to this article can be found on the Neurology
Web site. Go to www.neurology.org and scroll down the Table of Con-
tents for the March 20 issue to find the title link for this article.
Figure. Diffusion-weighted (A) and T2-
weighted imaging (B) of MR shows an
acute infarction restricted to the cerebel-
lar nodulus.
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weighted MRI disclosed a circumscribed acute infarction in the
cerebellar nodulus (figure). Other parts of the cerebellum and
the brainstem were intact. Over the following several days,
vertigo, PAN, and postural imbalance resolved.
Discussion. We observed PAN, perverted HSN, and impaired
tilt suppression of the postrotatory nystagmus in a patient with
isolated nodulus infarction. In monkeys, ablation of the cerebellar
nodulus gave rise to PAN in darkness.4 Since the nodulus nor-
mally inhibit the time course of rotationally induced nystagmus,
i.e., the velocity storage mechanism, PAN has been ascribed to
prolonged vestibular response after uvulonodular damage, and
reversal of the nystagmus by normal vestibular repair mecha-
nism, which would result in periodic oscillation of PAN.1,4
The postrotatory nystagmus is normally suppressed by head
tilting just after cessation of step-velocity rotation (tilt suppres-
sion). This suppressive effect is lost after ablation of the uvu-
lonodulus.4,5 Indeed, in our patient, TCs of the per- and
postrotatory nystagmus were mildly increased to an average of
18.3 seconds. Furthermore, TCs of the postrotatory nystagmus
were not diminished by head tilt after step velocity rotation.
In vestibulopathies, HSN can be induced by head oscillation at
2 Hz for approximately 20 seconds.1 In perverted HSN, HSN de-
velops in another plane than that being stimulated by head oscil-
lation. Perverted HSN is explained by abnormal cross-coupling of
vestibular responses that have usually been attributed to lesions
in the central vestibular pathways, including the vestibulocerebel-
lum.4,6 The uvulonodulus are also known to control spatial orien-
tation of the angular VOR and may participate in cross-coupling
of the velocity storage during head tilt.4 Damage to these areas
may induce abnormal activation of the cross-coupling during head
oscillation and result in perverted HSN.4
In our patient, PAN was present only without visual fixation.
However, most of the previously reported cases of PAN showed
little effect of visual fixation on the nystagmus. Cerebellar floccu-
lus is important for suppression of vestibular nystagmus by visual
fixation,7 and the disappearance of PAN with visual fixation in our
patient suggests intact floccular function. The absence of saccadic
dysmetria, gaze-evoked nystagmus, and spontaneous downbeat
nystagmus in our patient is also consistent with the integrity of
the oculomotor vermis and floccular region, and is suggestive of
isolated nodular dysfunction.
Previously, multiple cerebellar and brainstem lesions or dif-
fuse cerebellar atrophy have been reported with PAN.2,3 However,
despite the numerous reports on nodular dysfunction as a mecha-
nism of PAN, pathologic or radiologic confirmation of circum-
scribed nodular lesions has been unavailable in patients with
PAN. The PAN and associated findings in our patient with iso-
lated nodular infarction provide further evidence that PAN devel-
ops due to nodular dysfunction.
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Treatment-responsive pudendal dysfunction
in chronic inflammatory
demyelinating polyneuropathy
L. Bussemaker, MD; H.J. Schelhaas, MD, PhD;
S. Overeem, MD, PhD; W.P.M. Hopman, MD, PhD;
and M.J. Zwarts, MD, PhD
A 48-year-old man presented with sensory disturbances in both
hands and feet and difficulties when opening bottles or climbing
the stairs. His symptoms had developed over 2 weeks and were
preceded by fever of unknown origin. There was no history of toxin
exposure. His past medical history was remarkable for Henoch–
Schonlein purpura with nephritis and intestinal necrosis. Exami-
nation showed weakness of the neck, arm, and proximal leg
muscles (Medical Research Council [MRC] grade 4). Vibration
sense was diminished in both hands and feet, without a sensory
level. Tendon reflexes were absent. There were no gastrointestinal
symptoms, purpurae, or evidence of glomerulonephritis. Nerve
conduction studies showed that the distal motor latency (DML)
was increased in the median (5.6 milliseconds), ulnar (5.4 millisec-
onds), and peroneal nerves (19.2 milliseconds) and that the nerve
conduction velocity (NCV) was decreased in the median (32 m/s)
and peroneal (15.5 milliseconds) nerves, with conduction block
and sural sparing.1 The CSF was normal. Screening for syphilis
was negative. The patient was diagnosed with Guillain–Barre´
syndrome (GBS) and was treated with IV gammaglobulin (IVIG;
0.4 g/kg daily for 5 days), which led to almost complete resolution
of the muscle weakness within 3 weeks. Four weeks after dis-
charge, the patient was readmitted with similar but more severe
symptoms. In addition, he now reported fecal incontinence and a
diminished sense of stool passage. He also complained about new-
onset erectile dysfunction, but urinary function was normal. There
were no additional signs or symptoms of autonomic dysfunction.
There was weakness of both arms and legs (MRC grade 3 to 4),
absent distal vibration sense, and no tendon reflexes. Perianal
sensation was normal, but voluntary sphincter contraction was
nearly abolished. Nerve conduction studies showed an increased
DML and a reduced NCV in the median, ulnar, and peroneal
nerves, with conduction block in the median nerve. There were no
sural sensory nerve action potentials or ulnar F-responses. Con-
centric needle electromyography (EMG) of the external anal
sphincter revealed a reduced recruitment pattern both at rest and
during maximum contraction, without fibrillation potentials or
positive sharp waves. Lumbosacral magnetic stimulation showed
an increased latency over the left pudendal nerve (20 millisec-
onds) and no response on the right. MRI of the lumbar spine was
normal; nerve biopsy was not performed.
Anal manometry2 revealed a decreased resting pressure of
the internal sphincter (32 mm Hg; normal  2 SD 66  46 mm
Hg) and a decreased maximal squeeze pressure (a combination
of internal and external sphincter function; 57 mm Hg vs nor-
mal 218  140 mm Hg; figure). As a result, the maximal
squeeze increment was diminished (35 mm Hg; normal 90  64
mm Hg), indicating impaired voluntary contraction of the exter-
nal sphincter. Rectal sensitivity to balloon distension was not
affected.
Under the revised diagnosis of chronic inflammatory demy-
elinating polyneuropathy (CIDP), the patient was again treated
with IVIG. Three weeks later, muscle strength had increased,
fecal continence had improved, and erectile function had re-
turned to normal. Anal manometry showed a significant in-
crease in resting pressure (to 51 mm Hg), maximal squeeze
pressure (to 106 mm Hg), and maximal squeeze increment (to
80 mm Hg; figure). This was accompanied by an increase in
NCV and a nearly normalized recruitment pattern on needle
EMG. After 10 months, the patient had made a nearly full
recovery: He was continent and had only some residual numb-
ness in the feet with minimal toe weakness (MRC 4). Nerve
conduction studies still showed prolonged DMLs and reduced
NCVs, compatible with the diagnosis of CIDP.3,4
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Discussion. Our case shows that fecal incontinence caused by
bilateral demyelinization of the pudendal nerve can be part of the
clinical spectrum of CIDP. The onset, course, and response to
treatment paralleled the course of the motor and sensory symp-
toms. Furthermore, the EMG findings could only be explained by
a demyelinating disorder.
Prior to nerve conduction studies and anorectal manometry,
autonomic failure was considered the most likely cause of the
patient’s incontinence.5 However, although autonomic dysfunc-
tion is often pronounced in GBS,6 it is typically mild in CIDP.7
Moreover, both the EMG studies and the anal manometry
clearly pointed to the involvement of voluntary anal function.
In the past, “unequivocal incontinence” was considered an ex-
clusion criterion for CIDP.4 Although it is rare, fecal inconti-
nence can be present, and patients should be questioned about
it. If not, this treatable symptom may not be mentioned volun-
tarily by patients and certainly will not be picked up on routine
nerve conduction studies.
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Multiple sclerosis: Relating MxA transcription
to anti-interferon--neutralizing antibodies
L.A. Hoffmann, MD; M. Krumbholz, MD;
H. Faber; T. Kuempfel, MD; M. Starck, MD; W. Po¨llmann, MD;
E. Meinl, MD; and R. Hohlfeld, MD
Interferon- (IFN) treatment in multiple sclerosis (MS) induces
neutralizing antibodies (NAB) in 10 to 30% of patients.1,2 NAB are
associated with a reduction of bioactivity of IFN, and have a
negative impact on therapeutic response.3 Analysis of IFN-
inducible genes is a direct and practical approach to monitor
therapy.4,5 The expression of three IFN-induced genes in
antibody-positive patients with MS was recently analyzed.6 We
performed a similar study to evaluate the relationship between
the expression of myxovirus resistance protein A (MxA) and NAB
activity. Our results confirm and extend previously reported
results.6
Methods. We collected serum and PAXgene (PreAnalytiX/
Qiagen, Hilden, Germany) samples from 81 patients with
relapsing-remitting MS (RR-MS) (54 women, 27 men, median age
38, Expanded Disability Status Scale [EDSS] median 2.0, range 0
to 6.5) before (n  62) and 12 to 24 hours after (n  71) injection
of IFN (Avonex, n  12; Rebif, 3  22 g, n  13; Rebif, 3  44
g, n  39; Betaferon, n  17). Treatment duration was 	6
months in all cases. We also collected blood samples from 25
untreated control patients with RR-MS (19 women, 6 men, median
age 32 years, EDSS median 2.0, range 0.0 to 5.0). We analyzed
transcription of MxA and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) as housekeeping gene by TaqMan PCR (ABI 7300,
ABI, Darmstadt, Germany). We used the following MxA primers
and probes: forward 5=-GAGGAGATCTTTCAGCACCTGATG-3=,
reverse 5=-GTACGTCTGGAGCATGAAGAACTG-3=, probe Fam-
TCACCAGGAGGCCAGCAAGCG-Tamra (exon 19-20), and for
GAPDH as suggested by ABI. NAB analysis was performed at
BioMonitor (Copenhagen, Denmark) using a previously de-
scribed cytopathic effect assay (CPE), which measures the abil-
ity of NAB to counteract the protective effect of IFN when
cultured human A549 cells (subclone MC-5) are exposed to a
cytopathic IFN-sensitive virus (encephalomyocarditis virus).
Results are reported as neutralizing capacity (NC), which rep-
resents the percentage of the added IFN (10 LU/mL) neutral-
ized by the serum (5% v/v).7 All samples were tested for
endogenous cytotoxicity and intrinsic antiviral activity. NC be-
low 20% was regarded as negative, 20 to 79% as low positive,
and 80% or above as high positive. The laboratory workers who
performed the NAB assays were blinded with respect to the
MxA transcription data, and vice versa.
Results. Within a time frame of 12 to 48 hours, pilot experi-
ments (data not shown) showed maximum MxA transcription at
12 hours, with a moderate decrease at 24 hours postinjection
(about 50 to 80% of the 12-hour values). At 24 to 48 hours MxA
transcription further decreased, but was still above the basal lev-
els observed in untreated MS and control subjects. Blood sampling
before 12 hours postinjection is inconvenient for clinical routine
purposes, as injections are usually given in the evening. Therefore
Additional material related to this article can be found on the Neurology
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Figure. Results of anal manometry obtained with a stan-
dard station-pull-through technique with a water-
perfused catheter and radially oriented recording
points.2 Resting and squeeze pressures in the anal canal
were measured at consecutive 1-cm levels in four sepa-
rate quadrants. The highest resting pressure (resting P),
maximal squeeze pressure (P max; maximal pressure in
the anal canal during squeezing), and maximal squeeze
increment (delta P; increase of pressure over resting
pressure during squeezing) recorded in each quadrant
are depicted together with their average values. The
open symbols represent values before treatment with IV
gammaglobulin and filled symbols values after treat-
ment. Differences before and after treatment were tested
for statistical significance with Student t test.
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we chose a time window of 12 to 24 hours for blood sampling after
IFN injection.
We observed high positive NAB (	80% neutralizing capacity)
in 9, low positive NAB (20 to 80%) in 5, and negative NAB activity
(20%) in 67 patients. Patients with high positive NAB (	80%
neutralizing capacity) were distributed as follows: Avonex 0/12,
Betaferon 2/18, Rebif 7/52.
High levels of NAB (NABhigh) were associated with very low
MxA transcription, similar to untreated controls (figure, A; figure
E-1 on the Neurology Web site at www.neurology.org). Patients
with negative and low NAB activity (NABneg/low) had 18-fold
higher median MxA levels than untreated controls (figure, A).
We compared RNA extraction immediately after blood drawing
and storage of full blood in PAXgene tubes for up to 5 days. The
PAXgene system, which greatly simplifies the clinical application,
proved to give similar MxA levels as the immediate RNA extrac-
tion (data not shown). Analysis of whole blood gave a similar
sensitivity to detect IFN-mediated induction of MxA as analysis
of separated immune cell subsets (monocytes, lymphocytes, neu-
trophils) (data not shown). Analyzing the after/before ratio of MxA
values yielded no additional information compared to the absolute
MxA values after injection alone (figure, B and C).
Discussion. Our data confirm that measuring MxA tran-
scription in whole blood offers a practical method for monitor-
ing the bioactivity of all available IFN preparations. The
method allows reliable identification of NABhigh patients. Ex-
pression of MxA in NABneg/low patients was significantly higher
than in untreated controls and NABhigh patients. A time win-
dow between 12 to 24 hours proved to be practical for clinical
routine purposes, although a higher induction was seen after 12
hours. MxA induction in NABlow patients demonstrated sus-
tained bioactivity. While other studies used the Kawade6
method, we applied a simplified NAB CPE assay with results
reported in neutralizing capacity. Nevertheless, our results are
in full agreement with a recent study6 clearly demonstrating a
decrease of bioactivity in patients with NC above 80%. Thus, in
contrast to measuring NAB levels, measuring MxA levels is a
straightforward, easy to standardize tool for rating in vivo ef-
fects of IFN therapy.
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Figure. (A) Induction of myxovirus resistance protein A
(MxA) mRNA by interferon- (IFN) therapy in vivo in neu-
tralizing antibodies (NAB)neg/low patients, but not in
NABhigh patients. Expression of MxA as percentage of the
housekeeping gene GAPDH was analyzed for untreated con-
trols (median MxA 4% GAPDH), patients with negative or
low neutralizing antibodies (NABneg/low) before (median MxA
24%) and 12 to 24 hours after (median MxA 71%) IFN in-
jection, and patients with high NAB activity (NABhigh) before
(median MxA 3%) and 12 to 24 hours after (median MxA
4%) IFN injection. The results show a significant (analysis
of variance on ranks, Dunn test) decrease of bioactivity in the
NABhigh patients who had MxA expression levels similar to
untreated controls, whereas the NABneg/low patients show
clearly sustained bioactivity with increased MxA expression.
(B) Absolute MxA values after injection. (C) Ratio of MxA
values (MxA after/MxA before IFN injection). Analysis of
the ratio of MxA values (MxA after/MxA before IFN injec-
tion) does not yield additional information for discrimina-
tion of responders and nonresponders vs absolute MxA
values after injection. 
he lower ratios after/before for Be-
taferon and Rebif vs Avonex reflect differences of time inter-
vals to previous injection.
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Phenotypes of female adrenoleukodystrophy
H.H. Jung, MD; I. Wimplinger; S. Jung; K. Landau; A. Gal;
and F.L. Heppner
Adrenoleukodystrophy-adrenomyeloneuropathy (ALD-AMN) is an
X-linked disorder of the peroxisomal beta oxidation characterized
by the accumulation of saturated very long chain fatty acids (VL-
CFA) predominantly in adrenal cortex and central as well as pe-
ripheral myelin.1 ALD-AMN is caused by mutations of the ABCD1
gene, a member of the ATP-binding cassette (ABC) transporter
superfamily, and more than 400 pathogenic ABCD1 mutations
have been described (www.x-ald.nl).2
The incidence of ALD-AMN is estimated to be between
1:20,000 and 1:100,000. Affected men may present with childhood
cerebral ALD, adult-onset AMN, or Addison disease only.1,3 Ap-
proximately 20% of heterozygous women develop mild AMN with
a mean onset age around 40 years.1 Childhood onset, cognitive
decline, visual disturbances, or adrenal dysfunction are
exceptional.1,3,4
Herein, we describe two female ALD-AMN heterozygotes pre-
senting with particular cerebral phenotypes, thereby expanding
the clinical spectrum of female ALD-AMN and demonstrating a
substantial intrafamilial variability.
Case reports. Case 1. This patient was diagnosed with
manic-hebephrenic disorder at age 8 years, and had recurrent
psychotic episodes thereafter. At age 25 years, neurologic exami-
nation revealed spastic paraparesis. Twenty years later, neuro-
logic examination documented moderate cognitive deficits, severe
spastic paraparesis, and a cerebellar syndrome with unsteady
smooth pursuit gaze movements, dysarthria, and intention
tremor. Cerebral MRI showed moderate cerebellar atrophy and
pronounced T2 hyperintensities of the cerebellar white matter,
but no supratentorial atrophy or signal alterations. In the follow-
ing years, her condition gradually worsened and she died at age
51 years due to pneumonia.
Autopsy revealed severe demyelination in the cerebral and,
considerably more pronounced, the cerebellar white matter (fig-
ure). Histologically, cerebellar lesions were gliotic and depleted
of axons and oligodendroglia (figure, A, C, E, and G). Cerebral
lesions presented with clusters of foamy macrophages harbor-
ing myelin and reactive, often gemistocytic astrocytes (figure,
B, D, F, and H). While adrenal glands macroscopically appeared
normal, histologic examination revealed numerous adrenocorti-
cal cells with lamellar eosinophilic cytoplasmic inclusions (fig-
ure, I and J).
Her brother was diagnosed with Addison disease at age 47
years. He developed progressive spastic paraparesis and polyneu-
ropathy in his sixth decade. Electroneuromyography showed de-
myelinating polyneuropathy. Cognitive testing and cerebral MRI
were normal.
Case 2. At age 35 years, 1 year after her son died from
ALD, this patient became unable to run. Walking difficulties
increased and she became wheelchair-dependent at age 48
years. Seven years later, she noted progressive bilateral visual
loss. Neurologic examination revealed severe spastic tetrapare-
sis and mild polyneuropathy. Cognitive testing was normal.
Ophthalmologic examination demonstrated reduced visual acu-
ity (20/40 in the right eye, 20/30 in the left), severe diffuse
visual field impairment, and bilateral optic atrophy (OA). Visu-
ally evoked potentials demonstrated bilaterally prolonged P100
latencies (142 msec in the right eye, 135 msec in the left,
normal 118 msec). Cerebral MRI revealed bilateral parietooc-
cipital T2 hyperintensities (not shown).
Molecular genetic analysis. DNA was extracted from paraffin-
embedded tissue (Patient 1) or from whole blood (Patient 2). The
10 exons of the ABCD1 gene were amplified, mutation screening
was performed with single stranded DNA conformation sensitive
(SSCP) electrophoresis, and exons with abnormal SSCP conform-
ers were sequenced. In the brother of Patient 1, a point mutation
in exon 7 was found (c.1772G	A), predicting replacement of argi-
nine by glutamine (p.R591Q). Direct sequencing confirmed het-
erozygosity in Patient 1. In Patient 2, a heterozygous point
mutation in exon 2 was found (c.1039C	G), predicting replace-
ment of proline by arginine (p.P218R).
The methylation pattern at the androgen receptor (AR) locus
was examined as previously described with minor modifica-
tions.5 In Patient 1, moderately skewed patterns with values of
65:35 (liver) and 82:18 (kidney) were seen. Patient 2 demon-
strated a highly skewed X-inactivation with a ratio of 96:4.
Discussion. Both patients had adult-onset AMN, confirming
that spastic paraparesis represents the core feature in female
ALD-AMN. However, our observations emphasize a possibly ear-
lier onset and broader phenotypic spectrum. The first patient had
a childhood-onset psychiatric disorder and adult-onset olivoponto-
cerebellar syndrome due to predominant cerebellar involvement.
Similar manifestations are known in male ALD-AMN, but are
exceptional in manifesting heterozygous women.1,3,6 The second
patient had late-onset optic atrophy, which has formerly been
described only in male childhood-onset ALD. Since the brother of
the first patient had Addison disease and late-onset AMN, our
observations also document a remarkable intrafamilial phenotypic
variability.
Highly skewed X-inactivation was observed in one third of
symptomatic female ALD-AMN patients but not in asymptomatic
mutation carriers.4,7 Skewing of X-inactivation was therefore pro-
posed to correlate with clinical severity in ALD-AMN carriers.7 We
found a significantly skewed X-inactivation in the second patient,
whereas the first patient had only moderately skewing in liver
and kidney tissue. Although the sample origin might influence the
degree of X-inactivation, additional genetic or environmental fac-
tors have to be postulated to explain the phenotypic variability of
female ALD-AMN.
Our observations illustrate and broaden the phenotypic spec-
trum of manifesting female ALD-AMN carriers and underline the
importance to consider female ALD-AMN in the differential diag-
nosis of various neurologic disorders.
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Figure. Brain autopsy: coronal sections
of the cerebellum (A) and the cerebrum
(B) of Patient 1 depict sharply demar-
cated white matter lesions. Areas in A
and B indicate the corresponding mi-
croscopic regions. White matter lesions
in the cerebellum were extensive, par-
tially microcystic, did not affect the mo-
lecular and granular cell layers (ml
and gcl; hematoxylin and eosin, HE; C),
and were strongly gliotic as demon-
strated by positivity for glial fibrillary
acidic protein (GFAP; E). Only few re-
sidual CD68 macrophages remained
in these lesions (G). Cerebral lesions
located in the basal ganglia presented
with rather fresh and CD68 foamy
macrophage-rich lesions restricted to
the white matter (HE, D; Luxol-Nissl,
LN, F; CD68, H). Foamy macrophages
presented as myelinophages harboring
myelin (insert in F, spotted blue mate-
rial inside foamy macrophages). Adre-
nal gland: Microscopic appearance of
Patient’s one adrenal gland revealed
striated adrenocortical cells (I) contain-
ing lamellar eosinophilic cytoplasmic
inclusions (arrows in J); while bal-
looned cells were not visible (HE, I and
J). Scale bars: A and B: 1 cm; C: 1 mm;
D through I: 200 m; insert in F and J:
20 m.
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Homozygous mutation in MYH7 in myosin
storage myopathy and cardiomyopathy
Homa Tajsharghi, PhD; Anders Oldfors, MD, PhD;
Dominic P. Macleod, MB; and Michael Swash, MD
Myosin storage myopathy (MSM) associated with mutations in
MYH7 encoding for slow/-cardiac myosin heavy chain (MyHC)
occurs sporadically or shows autosomal dominant inheritance.1-4
MSM is usually associated with severe skeletal muscle weakness,
but cardiomyopathy is typically not present. We describe a patient
with MSM in whom there was a homozygous mutation
(Glu1,883Lys) in MYH7. The parents were second cousins, and
three of their children developed progressive MSM with respira-
tory muscle weakness and hypertrophic cardiomyopathy.
Clinical data. This British family consisted of four siblings,
three of whom were affected; the parents were second cousins. There
was no family history of muscle weakness. The father died with a
stroke at age 58 and the mother with myocardial infarct at age 70.
Case 1. Exertional dyspnea commenced in late adolescence for
this patient. She presented at age 26 in heart failure, with elevated
jugular venous pressure (8 cm), soft systolic murmur at the left
sternal edge, and fourth heart sound. She was short (height 141 cm),
with thoracic scoliosis. Lung function tests revealed a restrictive
deficit. EKG showed right bundle branch block, right axis deviation,
and sinus tachycardia. Echocardiography and cardiac catheterization
revealed hypertrophic, nonobstructive cardiomyopathy with elevated
right ventricular pressure (40 mm Hg systolic) and a restrictive right
and left ventricular pattern. Five years later, she developed an acute
supraventricular dysrthythmia. Examination at age 34 revealed
symmetric limb-girdle weakness and wasting, with mild calf hyper-
trophy, without myotonia. The blood creatine kinase (CK) level was
161 IU/L (normal  50 IU/L). Electromyography revealed myopathic
motor units. A deltoid muscle biopsy was taken. Her muscle weak-
ness progressed, and by age 45 she was wheelchair dependent. She
developed hypercapnic respiratory and cardiac failure requiring noc-
turnal volume-cycled nasal ventilatory support, with anti-arrhythmic
and diuretic therapy. She died at age 57 in cardiorespiratory failure.
Case 2. The younger brother of Case 1 presented at age 25 in
acute pulmonary edema following general anesthesia after a trau-
matic fracture. There was a history of daytime somnolence and
headache, with exertional dyspnea. Examination revealed short
stature, mild thoracic scoliosis, and mild proximal weakness and
wasting. The CK level was 201 IU/L (normal  160 IU/L). Inves-
tigation revealed biventricular hypertrophic cardiomyopathy. He
died at age 32 from cardiac failure.
Case 3. This brother presented at age 44 with daytime som-
nolence, leg weakness, and hypercapnic respiratory failure, re-
quiring urgent tracheotomy and ventilatory support. He was of
short stature (height 155 cm), with a myopathic facies, a high-
arched palate, thoracic scoliosis, a weak sniff test, and proximal
muscle weakness and wasting, but no myotonia. The CK level was
	3,000 IU/L (normal  160 IU/L). Investigation revealed biven-
tricular hypertrophic cardiomyopathy and heart failure. He was
managed with nasal positive pressure ventilation and diuretic
therapy. A biceps brachii muscle biopsy was performed.
Muscle biopsy findings. Muscle samples from the three sib-
lings showed similar findings typical for MSM. Hyaline bodies
were seen in type 1 fibers, but not in type 2 fibers, consisting of
amorphous eosinophilic material, faintly green in Gomori
trichrome, negative in oxidative enzyme preparations and periodic
acid–Schiff, but faintly positive in ATPase preincubated at pH 4.3.
Immunostains for titin, nebulin, and -actinin were negative. Elec-
tron microscopy revealed moderately electron-dense, nonfilamentous,
finely granular amorphous material that seemed to infiltrate myofi-
brils. Cardiac muscle from Case 2 at autopsy showed fibrosis, loss of
myocytes, and hyaline bodies in remaining myocytes.
Genetic findings. The entire coding sequence of MYH7 in
genomic DNA was sequenced in Case 3.1 We identified a homozy-
gous missense mutation in exon 38 (24,012G¡A), changing the
highly conserved and negatively charged glutamate at position
1,883 to the positively charged lysine (figure E-1 on the Neurology
Web site [www.neurology.org]). The Glu1,883Lys mutation is located
in the distal end of the filament forming rod region of slow/-cardiac
MyHC, in the 29-residue assembly-competence domain (1,871 to
1,899), which is essential for filament assembly5 (figure E-1).
Accession numbers were for genomic MYH7 sequence aj238393
and for cDNA MYH7 sequence m58018.
Discussion. This family with MSM presented with type II respi-
ratory failure and cardiac failure, due to hypertrophic cardiomyopa-
thy, associated with a homozygous mutation in the distal rod region
of slow/-cardiac MyHC. The mode of inheritance differs from previ-
ously described patients with MSM and MYH7 mutations. The par-
ents were unaffected second cousins. The investigated sibling was
homozygous for the mutation, suggesting autosomal recessive inher-
itance. The previously reported cases with MSM associated with
MYH7mutations were heterozygous for the mutation, and dominant
inheritance was demonstrated for these mutations. Previously re-
ported patients with dominantly inherited MSM associated with
MYH7 mutations have not developed cardiomyopathy or type II re-
spiratory failure, suggesting that the phenotypes of recessively and
dominantly inherited cases differ. The majority of MYH7 mutations
are dominant and associated with cardiomyopathy, but there are
reported examples of mutations in MYH7, without skeletal myop-
athy, causing severe cardiomyopathy in homozygotes but only mild
or no signs of cardiomyopathy in heterozygotes.6 In the family with
MSM reported here, genetic analysis could only be performed in Case 3,
and therefore we cannot rule out heterozygosity in the other siblings.
Although previously reported patients with MSM associated with
different MYH7 mutations did not show cardiomyopathy, this is not
unique, as in Laing early-onset distal myopathy, caused by muta-
tions in another region of MYH7, cardiac involvement is absent.7
As in previously reported patients with MSM, the mutated resi-
due is located in a b-, f-, or c-position in the coiled-coil structure of the
distal rod region of the MyHC dimer (figure E-1). Residues in these
positions may interact with other MyHC dimers or myosin binding
proteins, explaining why mutations affecting such residues can cause
defective assembly of thick filaments. The previously reported cases
were all heterozygous for the mutation, whereas our Case 3 was
homozygous. The parents were second cousins and therefore proba-
bly unaffected heterozygous carriers of the mutation, indicating that
the Glu1,883Lys mutation is less pathogenic in recessive form than
the previously reportedMYH7 mutations associated with MSM. Our
findings suggest that the mutated residue Glu1,883, which is located
within the assembly-competence domain of the MyHC,5 is important
for thick filament assembly both in skeletal and in cardiac muscle.
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